Asset Details
Do you wish to reserve the book?
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
Do you wish to request the book?
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
2022
Overview
Gadolinium-based contrast agents (GBCAs) have transformed magnetic resonance imaging (MRI) by facilitating the use of contrast-enhanced MRI to allow vital clinical diagnosis in a plethora of disease that would otherwise remain undetected. Although over 500 million doses have been administered worldwide, scientific research has documented the retention of gadolinium in tissues, long after exposure, and the discovery of a GBCA-associated disease termed nephrogenic systemic fibrosis, found in patients with impaired renal function. An understanding of the pharmacokinetics in humans and animals alike are pivotal to the understanding of the distribution and excretion of gadolinium and GBCAs, and ultimately their potential retention. This has been well studied in humans and more so in animals, and recently there has been a particular focus on potential toxicities associated with multiple GBCA administration. The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Biomedical and Life Sciences
/ Contrast Media - administration & dosage
/ Contrast Media - pharmacokinetics
/ Fibrosis
/ Gadolinium - administration & dosage
/ Gadolinium - pharmacokinetics
/ Humans
/ Magnetic Resonance Imaging - methods
/ Nephrogenic Fibrosing Dermopathy - etiology
/ Occupational Medicine/Industrial Medicine
/ Renal Insufficiency - complications
/ Review
/ Toxicity
